[go: up one dir, main page]

WO2004078166A3 - Use of omega-3-fatty acids in the treatment of diabetic patients - Google Patents

Use of omega-3-fatty acids in the treatment of diabetic patients Download PDF

Info

Publication number
WO2004078166A3
WO2004078166A3 PCT/EP2004/050238 EP2004050238W WO2004078166A3 WO 2004078166 A3 WO2004078166 A3 WO 2004078166A3 EP 2004050238 W EP2004050238 W EP 2004050238W WO 2004078166 A3 WO2004078166 A3 WO 2004078166A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acids
omega
treatment
diabetic patients
ethyl ester
Prior art date
Application number
PCT/EP2004/050238
Other languages
French (fr)
Other versions
WO2004078166A2 (en
Inventor
Rainer Oelze
Cees-Nico Verboom
Original Assignee
Solvay Pharm Gmbh
Rainer Oelze
Cees-Nico Verboom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh, Rainer Oelze, Cees-Nico Verboom filed Critical Solvay Pharm Gmbh
Priority to MXPA05009432A priority Critical patent/MXPA05009432A/en
Priority to CA002515328A priority patent/CA2515328A1/en
Priority to AU2004216856A priority patent/AU2004216856A1/en
Priority to JP2006505440A priority patent/JP2006519244A/en
Priority to EP04737282A priority patent/EP1603551A2/en
Priority to BRPI0408006-8A priority patent/BRPI0408006A/en
Publication of WO2004078166A2 publication Critical patent/WO2004078166A2/en
Publication of WO2004078166A3 publication Critical patent/WO2004078166A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) useful for preventing of cardiovascular events in patients with diabetes mellitus.
PCT/EP2004/050238 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients WO2004078166A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05009432A MXPA05009432A (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients.
CA002515328A CA2515328A1 (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients
AU2004216856A AU2004216856A1 (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients
JP2006505440A JP2006519244A (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients
EP04737282A EP1603551A2 (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients
BRPI0408006-8A BRPI0408006A (en) 2003-03-05 2004-03-02 use of omega-3 fatty acids in the treatment of diabetic patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004792.2 2003-03-05
EP03004792 2003-03-05

Publications (2)

Publication Number Publication Date
WO2004078166A2 WO2004078166A2 (en) 2004-09-16
WO2004078166A3 true WO2004078166A3 (en) 2004-10-28

Family

ID=32946844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050238 WO2004078166A2 (en) 2003-03-05 2004-03-02 Use of omega-3-fatty acids in the treatment of diabetic patients

Country Status (8)

Country Link
EP (1) EP1603551A2 (en)
JP (1) JP2006519244A (en)
CN (1) CN1756545A (en)
AU (1) AU2004216856A1 (en)
BR (1) BRPI0408006A (en)
CA (1) CA2515328A1 (en)
MX (1) MXPA05009432A (en)
WO (1) WO2004078166A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377920B2 (en) 2009-02-10 2013-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8410086B2 (en) 2009-06-15 2013-04-02 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US8445013B2 (en) 2009-04-29 2013-05-21 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8563608B2 (en) 2009-04-29 2013-10-22 Amarin Pharmaceuticals Ireland Limited Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP4954714B2 (en) 2005-01-04 2012-06-20 持田製薬株式会社 Lipid toxicity improver
CN101213281B (en) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 New dha derivatives and their use as medicaments
EP1888727B1 (en) * 2005-05-04 2015-04-15 Pronova BioPharma Norge AS New dha derivatives and their use as medicaments
KR101255650B1 (en) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 New DHA derivatives and their use as medicaments
RU2441061C2 (en) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Docosahexaenoic acid derivatives and their application as drugs
KR101465715B1 (en) * 2005-07-08 2014-11-27 모치다 세이야쿠 가부시키가이샤 Composition for preventing cardiovascular event occurrence
JP5134916B2 (en) * 2005-07-08 2013-01-30 持田製薬株式会社 Composition for preventing cardiovascular events
RU2507193C2 (en) * 2006-11-01 2014-02-20 Пронова Биофарма Норге А/С Alpha-substituted omega-3 lipids, activators or modulators of peroxisome proliferator activated receptor (ppar)
BRPI0717883A2 (en) * 2006-11-01 2013-10-29 Pronova Biopharma Norge As LIPID COMPOUNDS, COMPOSITION CONTAINING THE SAME AND USE OF SUCH COMPOUNDS
US8399516B2 (en) 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
MX2009004339A (en) * 2006-11-03 2009-05-20 Pronova Biopharma Norge As Fatty acid alcohols.
WO2010018856A1 (en) * 2008-08-13 2010-02-18 持田製薬株式会社 Prophylactic/ameliorating or therapeutic agent for cannabinoid receptor-related disease
PL2334295T3 (en) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
FR2949063B1 (en) * 2009-08-11 2011-09-30 Pf Medicament PHARMACEUTICAL COMPOSITION COMPRISING A DHA ESTER FOR PARENTERAL ADMINISTRATION
MX2012003555A (en) 2009-09-23 2012-07-03 Amarin Corp Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same.
CN103338762B (en) * 2010-11-09 2015-03-25 持田制药株式会社 Suppressor for increase in blood glucose level
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
ES2993235T3 (en) 2012-06-29 2024-12-26 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20240135078A (en) 2018-09-24 2024-09-10 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the risk of cardiovascular events in a subject
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60248610A (en) * 1984-05-23 1985-12-09 Nitsusui Seiyaku Kk Preventive and remedy for complicated diabetes
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60248610A (en) * 1984-05-23 1985-12-09 Nitsusui Seiyaku Kk Preventive and remedy for complicated diabetes
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198604, Derwent World Patents Index; Class B05, AN 1986-025591, XP002249968 *
MALASANOS T H ET AL: "BIOLOGICAL EFFECTS OF OMEGA-3 FATTY ACIDS IN DIABETES MELLITUS", DIABETES CARE, vol. 14, no. 12, 1991, pages 1160 - 1179, XP009014817, ISSN: 0149-5992 *
MANN J I: "Diet and risk of coronary heart disease and type 2 diabetes", LANCET, XX, XX, vol. 360, no. 9335, 7 September 2002 (2002-09-07), pages 783 - 789, XP004379893, ISSN: 0140-6736 *
NOSARI I ET AL: "[Use of omega-3 in diabetic patients]", LA CLINICA TERAPEUTICA. ITALY MAR 1994, vol. 144, no. 3, March 1994 (1994-03-01), pages 213 - 221, XP009014816, ISSN: 0009-9074 *
PEPPING J: "Omega-3 essential fatty acids.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY: AJHP: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. UNITED STATES 15 APR 1999, vol. 56, no. 8, 15 April 1999 (1999-04-15), pages 719 - 720, 723 - 724, XP009014829, ISSN: 1079-2082 *
SIRTORI C R ET AL: "N-3 fatty acids and diabetes.", BIOMEDICINE & PHARMACOTHERAPY, vol. 56, no. 8, 20 October 2002 (2002-10-20), pages 397 - 406, XP001153938, ISSN: 0753-3322 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440650B1 (en) 2009-02-10 2013-05-14 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8399446B2 (en) 2009-02-10 2013-03-19 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8377920B2 (en) 2009-02-10 2013-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8415335B2 (en) 2009-02-10 2013-04-09 Amarin Pharmaceutical Ireland Limited Methods of treating hypertriglyceridemia
US8426399B2 (en) 2009-02-10 2013-04-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8431560B1 (en) 2009-02-10 2013-04-30 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8563608B2 (en) 2009-04-29 2013-10-22 Amarin Pharmaceuticals Ireland Limited Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US8663662B2 (en) 2009-04-29 2014-03-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US8454994B2 (en) 2009-04-29 2013-06-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8613945B2 (en) 2009-04-29 2013-12-24 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8617593B2 (en) 2009-04-29 2013-12-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8618166B2 (en) 2009-04-29 2013-12-31 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8642077B2 (en) 2009-04-29 2014-02-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8445013B2 (en) 2009-04-29 2013-05-21 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8691871B2 (en) 2009-04-29 2014-04-08 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8710041B2 (en) 2009-06-15 2014-04-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
US8410086B2 (en) 2009-06-15 2013-04-02 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Also Published As

Publication number Publication date
AU2004216856A1 (en) 2004-09-16
MXPA05009432A (en) 2005-11-23
WO2004078166A2 (en) 2004-09-16
EP1603551A2 (en) 2005-12-14
CA2515328A1 (en) 2004-09-16
CN1756545A (en) 2006-04-05
JP2006519244A (en) 2006-08-24
BRPI0408006A (en) 2006-02-14

Similar Documents

Publication Publication Date Title
WO2004078166A3 (en) Use of omega-3-fatty acids in the treatment of diabetic patients
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
WO2008018043A3 (en) Methods of improving bone health and muscle health
EP2258447A3 (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
CA2362271A1 (en) Essential fatty acids in the prevention of cardiovascular events
EP2510927A3 (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
IL210233A (en) Omega-3 fatty acid formulations containing epa and dha and no active ingredients other than omega-3 fatty acids
BRPI0418921A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a
DE60212786D1 (en) Use of polyunsaturated fatty acids for the primary prevention of cardiovascular seizures
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
EP1698685A4 (en) Fat composition
DE69622722D1 (en) Dietary composition containing fats for the treatment of the metabolic syndrome
WO2007073175A3 (en) Composition comprising polyunsaturated fatty acids for improving membrane composition
WO2004028469A3 (en) Docohexaenoic acid for improved glycemic control
WO2005107875A3 (en) Triglycerides, fatty acids, alcohols as cns modulators
EP1544281A4 (en) Fat composition
AU7427601A (en) Therapeutic combinations of fatty acids
WO2003105776A3 (en) ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
EP1765324A4 (en) Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids
EP1709952B8 (en) Composition containing polyglycerol/medium-chain fatty acid ester
EP1504677A4 (en) Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof and vegetable fat composition containing the same
WO2005122791A3 (en) Improvement of barrier integrity in hiv patients with fatty acids
AU2441400A (en) Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same
NZ598529A (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
WO2002092779A3 (en) Method for enriching tissues in long chain polyunsaturated fatty acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2515328

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048055600

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004737282

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009432

Country of ref document: MX

Ref document number: 2006505440

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004216856

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004216856

Country of ref document: AU

Date of ref document: 20040302

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216856

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004737282

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408006

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004737282

Country of ref document: EP